Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Assets (2019 - 2025)

Historic Assets for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $138.3 million.

  • Pulmonx's Assets fell 1739.54% to $138.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.3 million, marking a year-over-year decrease of 1739.54%. This contributed to the annual value of $162.8 million for FY2024, which is 839.85% down from last year.
  • Per Pulmonx's latest filing, its Assets stood at $138.3 million for Q3 2025, which was down 1739.54% from $147.2 million recorded in Q2 2025.
  • In the past 5 years, Pulmonx's Assets registered a high of $255.3 million during Q1 2021, and its lowest value of $138.3 million during Q3 2025.
  • Over the past 5 years, Pulmonx's median Assets value was $193.1 million (recorded in 2023), while the average stood at $193.6 million.
  • Per our database at Business Quant, Pulmonx's Assets skyrocketed by 24644.04% in 2021 and then crashed by 1822.81% in 2024.
  • Quarter analysis of 5 years shows Pulmonx's Assets stood at $235.2 million in 2021, then fell by 17.65% to $193.7 million in 2022, then decreased by 8.21% to $177.8 million in 2023, then decreased by 8.4% to $162.8 million in 2024, then dropped by 15.09% to $138.3 million in 2025.
  • Its Assets stands at $138.3 million for Q3 2025, versus $147.2 million for Q2 2025 and $150.7 million for Q1 2025.